The rank abundance curves of four demonstrative samples that successfully pass the neutrality test.

<p>The four samples were selected from four different individual subjects among 3 treatments: 1 from the BoP treatment (Subject ID: 1PB), 1 from the Non-BoP (Subject ID: 3PnB), and 2 from the healthy treatment (Subject ID: 25H2, 28H2), the solid red line represents for the observed data and the black dash lines for the simulated datasets. The <i>X</i>-axis is the species rank order in abundance and <i>Y</i>-axis is the abundance of each species in natural logarithm.</p

The “flip-flop” of the neutrality test results with Etienne formula with 100/1000 artificial communities^*.

<p>The “flip-flop” of the neutrality test results with Etienne formula with 100/1000 artificial communities^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0182259#t003fn001" target="_blank">*</a>}.</p

The average values of the fundamental diversity parameter (<i>θ</i>) in the three treatments obtained with Etienne sampling formula: significant differences between control (healthy) and BoP (periodontitis with BoP), as well as between control (healthy) and Non-BoP (periodontitis without BoP) were detected (The Bonferroni pair-wise comparison with <i>p</i><0.01).

<p>The average values of the fundamental diversity parameter (<i>θ</i>) in the three treatments obtained with Etienne sampling formula: significant differences between control (healthy) and BoP (periodontitis with BoP), as well as between control (healthy) and Non-BoP (periodontitis without BoP) were detected (The Bonferroni pair-wise comparison with <i>p</i><0.01).</p

The 14 communities that passed the neutrality exact tests with both Ewens and Etienne sampling formulae (with 100 artificially simulated communities)^*.

<p>The 14 communities that passed the neutrality exact tests with both Ewens and Etienne sampling formulae (with 100 artificially simulated communities)^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0182259#t001fn001" target="_blank">*</a>}.</p

The 13 communities that passed the neutrality exact tests with Etienne sampling formula with 1000 artificially simulated communities^*.

<p>The 13 communities that passed the neutrality exact tests with Etienne sampling formula with 1000 artificially simulated communities^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0182259#t002fn001" target="_blank">*</a>}.</p

Additional file 2: of MicroRNA-29b-2-5p inhibits cell proliferation by directly targeting Cbl-b in pancreatic ductal adenocarcinoma

Table S1. Clinical characteristics of the PDAC patients. (DOCX 18 kb

Additional file 1: of MicroRNA-29b-2-5p inhibits cell proliferation by directly targeting Cbl-b in pancreatic ductal adenocarcinoma

Figure S2. The identification of miRNAs. A. The flowchart of miRNA selection and schematic design. B. In the 18 candidate miRNAs, 2 miRNAs were opposite from the miRNA array, 16 were coherent with the miRNA array by Real-time PCR. Good prognosis group/poor prognosis. C. Among the candidate miRNAs, miR-891b and miR-490-5p could inhibit proliferation in cell lines. (PDF 426 kb

Additional file 4: of MicroRNA-29b-2-5p inhibits cell proliferation by directly targeting Cbl-b in pancreatic ductal adenocarcinoma

Figure S3. Increased expression of miR-29b-2-5p upon infection in 2 PDAC cell lines was confirmed by qRT-PCR. (mean ± SD, results of three independent experiments, *P < 0.05). (PDF 33 kb